Flumequine

Flumequine

SCHEMBL29465201

CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
CYP1A2 P05177 1/20 1.00
PDE4A P27815 1/20 0.61
PDE4B Q07343 1/20 0.61
PDE4C Q08493 1/20 0.61
PDE4D Q08499 1/20 0.61
LMNA P02545 1/20 0.57
HTR2A P28223 2/20 0.54
HTR2C P28335 2/20 0.54
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 2/20 0.48
ALB P02768 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
TUBB4A P04350 1/20 0.48
POLB P06746 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flumequine SCHEMBL30767693 1.00 KDM4E (1.00) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL49830 1.00 KDM4E (1.00) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL49829 1.00 KDM4E (1.00) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL29024599 0.99 KDM4E (0.98) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL29171109 0.99 KDM4E (0.98) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL27620591 0.92 KDM4E (0.84) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL11742001 0.89 KDM4E (0.80) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL11747062 0.89 KDM4E (0.80) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Flumequine SCHEMBL28121700 0.89 KDM4E (0.79) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
Water SCHEMBL11746655 0.88 KDM4E (0.79) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3686290-B1 METHOD AND KITS FOR IDENTIFYING CDK9 INHIBITORS FOR THE TREATMENT OF CANCER MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-08-23 EP claimed
CN-114594179-B Method for simultaneously and rapidly extracting and detecting multiple antibiotics in soil 农业农村部环境保护科研监测所 2023-08-18 CN claimed
CN-116234444-A Mixtures with insecticidal activity comprising sulfur-containing heterocyclylalkoxy compounds, oxides or salts thereof 皮埃企业有限公司 2023-06-06 CN claimed
US-20250255174-A1 LIGHT-EMITTING DEVICE, ELECTRONIC APPARATUS INCLUDING THE SAME, AND ORGANOMETALLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2025-08-07 US disclosed
CN-120142412-A Stabilizing oxygen in a composition 仪器实验室公司 2025-06-13 CN disclosed
CN-112469436-B Multivalent influenza nanoparticle vaccine 诺瓦瓦克斯股份有限公司 2025-03-14 CN disclosed
CN-119487005-A Pyrazole compound, intermediate for producing same, and pest control agent 日产化学株式会社 2025-02-18 CN disclosed
CN-119455915-A Purification device for cultivation tail water containing antibiotic medicine and control method thereof 福建省水产研究所(福建水产病害防治中心) 2025-02-18 CN disclosed
CN-119371678-A Hydrophilic magnetic polymer and preparation method and application thereof 福建省水产研究所(福建水产病害防治中心) 2025-01-28 CN disclosed
CN-119136833-A Membrane translocation domain and uses thereof 俄亥俄州创新基金会 2024-12-13 CN disclosed
CN-118515662-A Bactericidal compound based on pseudomonas aeruginosa, and preparation method and application thereof 华中农业大学 2024-08-20 CN disclosed
CN-109890807-B Heterocyclic substituted bicyclic azoles as pesticides FMC 公司 2023-04-04 CN disclosed
CN-115885033-A Bacterial strain belonging to the genus bacillus and microbial control agent using the same 国立大学法人东海国立大学机构 2023-03-31 CN disclosed
EP-4146820-A1 METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES The Trustees of The University of Pennsylvania (US) 2023-03-15 EP disclosed
EP-4110330-A1 ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF Gregg, John Malcolm Hall (US) 2023-01-04 EP disclosed
CN-115551353-A Substituted tolyl fungicides and mixtures thereof FMC公司 2022-12-30 CN disclosed
CN-110257269-B Paenibacillus for producing bacteriocin and application thereof 屏东科技大学 2022-11-25 CN disclosed
CN-114728011-A Preparations comprising steroid dimers and uses thereof in therapeutic agent delivery 波纹疗法公司 2022-07-08 CN disclosed
CN-114615891-A High-potency formulations based on 2- [ (2, 4-dichlorophenyl) methyl ] -4,4' -dimethyl-3-isoxazolidone and a pre-emergent herbicide 拜耳公司 2022-06-10 CN disclosed
US-11285133-B2 2- or 3-imidazolines as carbapenemases inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11285133-B2 2- or 3-imidazolines as carbapenemases inhibitors PADI3, PADI1, RPIA KDM4E 1162/4885SMN1; SMN2 1956/4885CYP1A2 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.